Appointment of Ms Janine Rolfe to the Cynata Board of Directors Melbourne, Australia; 30 August 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the appointment of Ms Janine Rolfe as an independent Non-Executive Director, effective 1 September 2022.
Ms Rolfe said: “I am delighted to be joining Cynata at a time when the Company’s robust clinical product development pipeline is advancing rapidly, and the Company’s commercial and strategic opportunities continue to progress. Cynata is the global leader in the development of induced pluripotent stem cell (iPSC) derived cell therapy products and I am very excited to be involved in the next stage of the Company’s growth.”
Ms Rolfe brings to the Cynata Board over two decades’ legal, governance and management experience across multiple sectors, including highly regulated industries and complex global businesses. Before recently transitioning as a professional non-executive director,
Ms Rolfe’s last executive position was General Counsel & Company Secretary of Link Administration Holdings Limited (Link Group). Prior to that, Ms Rolfe founded Company Matters Pty Limited and worked both in-house (Qantas Airways Limited) and in private practice (Mallesons Stephen Jaques, now King & Wood Mallesons), across a diverse and distinguished career.
Dr Geoff Brooke, Cynata’s Chairman, said: “Cynata continues to build a team with proven leadership capabilities and with Janine joining the Board of Directors we welcome a new skill set and contemporary outlook. Janine’s extensive experience in M&A, governance and growth businesses will add a new depth of talent to the Company at a very exciting time in our maturation. We welcome Janine to the Board and look forward to her contributions toward the advancement of Cynata and the flourishing Cymerus™ product pipeline.”
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)